Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia

NCT01741545 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus

Interventions

BIOLOGICAL: Pegylated-Interferon-lambda
DRUG: Ribavirin
DRUG: Daclatasvir

Sponsor

Bristol-Myers Squibb